53963-43-2

Basic information

• Product Name: GINSENOSIDEF1
• Synonyms: (20S)-20-(β-D-Glucopyranosyloxy)dammar-24-ene-3β,6α,12β-triol;3β,6α,12β-Trihydroxy-5α-dammar-24-en-20-yl β-D-glucopyranoside;(3b,6a,12b)-3,6,12-Trihydroxydammar-24-ene-20-yl beta-D-glucopyranoside;Ginsenoside F1;GINSENOSIDE F1(P);20(S)-Ginsenoside F1(3b,6a,12b)-3,6,12-Trihydroxydammar-24-ene-20-yl beta-D-glucopyranoside;20(S)-Ginsenoside F1;Panaxoside Aprogenin
• CAS NO: 53963-43-2
• Molecular Formula: C₃₆H₆₂O₉
• Molecular Weight: 638.87
• Product Categories: chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract
• Mol File: 53963-43-2.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 752.9°Cat760mmHg
• Flash Point: 409.1°C
• Appearance: /
• Density: 1.23g/cm³
• Vapor Pressure: 3.65E-26mmHg at 25°C
• Refractive Index: 1.58
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly )
• PKA: 12.94±0.70(Predicted)
• CAS DataBase Reference: GINSENOSIDEF1(CAS DataBase Reference)
• NIST Chemistry Reference: GINSENOSIDEF1(53963-43-2)
• EPA Substance Registry System: GINSENOSIDEF1(53963-43-2)

Safety Data

• Hazardous Substances Data: 53963-43-2(Hazardous Substances Data)

Usage

Uses

Ginsenoside F1 is a bioactive metabolite of the ginsenoside component of Panax ginseng with the ability to inhibit human cytochrome P450 enzymes. This has application in anti-cancer therapeutics as well as protective liver effects.

Definition

ChEBI: A ginsenoside found in Panax species that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions, in which the hy roxy group at position 20 has been converted to the corresponding beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position.

InChI:InChI=1/C36H62O9/c1-19(2)10-9-12-36(8,45-31-28(43)27(42)26(41)24(18-37)44-31)35(7)15-14-34(6)21-16-22(38)29-32(3,4)25(40)11-13-33(29,5)20(21)17-23(39)30(34)35/h10,20-31,37-43H,9,11-18H2,1-8H3/t20?,21?,22-,23+,24-,25?,26-,27-,28-,29?,30-,31+,33-,34-,35+,36-/m1/s1

Upstream product

• 52286-59-6 ginsenoside Re 
• 22427-39-0 ginsenoside-Rg₁ 

Relevant articles and documents

Characterization of metabolism and in vitro permeability study of notoginsenoside R1 from radix notoginseng

As a main and characteristic constituent in Radix notoginseng, the fate of notoginsenoside R1 (NGR1) in human is largely unknown. The present study investigated, for the first time, NGR1 metabolism by human intestinal bacteria and liver subcellular fractions, and permeability properties of NGR1 and resultant metabolites on a Caco-2 model. Samples were qualitatively analyzed using HPLC-MS/MS and quantitatively determined using HPLC-UV. When incubated with pooled human intestinal bacteria anaerobically, NGR1 showed biphasic elimination: an insignificant decrease in the first 8 h followed by a rapid elimination during 8-48 h. Four metabolites, three unambiguously identified as ginsenosides Rg1, F1 and 20(S)-protopanaxatriol formed via stepwise deglycosylation, and one tentatively assigned as a dehydrogenated protopanaxatriol with transformation occurring at the tetracyclic triterpenoid skeleton, were produced sequentially. Rg1 and F1 were formed transiently at low apparent velocities, while 20(S)-protopanaxatriol was the major metabolite with a formation rate close to the rate of NGR1 elimination and a low elimination rate. NGR1 remained intact in human liver S9 or microsomes over 1 h. Transport study of NGR1 and its metabolites revealed an ascending permeability order with stepwise deglycosylation. Taken together, the results revealed a determinant role of intestinal bacteria in the overall disposition and potential bioactivity of NGR1 in human.